Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 1 of the 34 sources its claims cite were checked for support.
Abstract
PURPOSE: Immune checkpoint inhibitors (ICIs) are frequently used to treat metastatic solid tumors characterized by high tumor mutational burden (TMB) and/or mismatch repair (MMR) deficiency. Most of the literature on their benefit is about carcinomas and melanomas, but little is known about their effects on sarcomas in these settings. In this study, we examined the response pattern to ICI-based therapy in sarcomas with those characteristics. Methods: Patients treated in our institution with ICI-based therapy for sarcomas with high TMB and/or MMR deficiency were identified. We analyzed the main outcome of interest, radiologic response to therapy, alongside clinical information including treatment type and duration, histologic diagnosis, germline and somatic MMR deficiency, and ultraviolet A (UVA) mutational signature. RESULTS: Among 17 patients identified, TMB ranged from 9 to 151 mut/Mb. Radiologic response was observed in 6 patients. TMB of responding patients ranged from 15-75 mut/Mb. The only responding case of MMR deficiency was seen in the one patient diagnosed with Lynch syndrome. By contrast, none of the five cases of sporadic MMR deficiency responded. The three complete responses were seen in MMR-proficient tumors associated with UVA signature and high TMB. CONCLUSION: Overall, sarcomas with MMR deficiency and/or high TMB show a heterogeneous pattern of responses to ICI-based therapy. Other cellular and molecular factors, such as histology, germline factors, and mutation signatures, likely contribute to the response to ICI treatment in sarcomas.
Overview
CoChat Summary
## TL;DR
This retrospective single-center case series examined immune checkpoint inhibitor (ICI) responses in 17 patients with metastatic sarcomas selected for high tumor mutational burden (TMB) and/or mismatch repair deficiency (MMR-D). Objective responses occurred in 6 of 17 patients, but responses clustered in tumors with ultraviolet A (UVA) mutation signatures and in one germline Lynch syndrome case, suggesting TMB/MMR-D alone were not sufficient predictors.
## Key findings
- Among 17 patients, 6 had objective responses to ICI therapy: 3 complete responses and 3 partial responses; 2 had stable disease and 9 had primary progression.
- Of the 16 high-TMB cases (TMB 10 to 151 mutations/Mb; one case had TMB 9), 6 responded, which the authors report as 37%.
- Of the 6 MMR-D cases, 1 responded; this response was in the single patient with germline MMR deficiency / Lynch syndrome, while none of the somatic MMR-D cases showed radiologic response.
- The 3 complete responses occurred in MMR-proficient tumors with UVA signatures: 2 pleomorphic dermal sarcomas and 1 cutaneous angiosarcoma; the authors note that all four cases with a UVA signature responded.
## Methods
- Design: Retrospective chart review at a single cancer center, approved by the Institutional Review Board.
- Sample/data: 17 patients aged 30–73 years, all with metastatic sarcoma; inclusion required TMB ≥10 mutations/Mb or MMR-D by next-generation sequencing, with biomarkers mostly confirmed on tumor samples and in one case by liquid biopsy.
- Analysis: Investigators assessed response using published real-world response criteria based on imaging (mostly CT every ~6 weeks; PET-CT for angiosarcoma of bone) and summarized responses by TMB, MMR status, histology, and mutation signature.
## Limitations
- The paper states that the sample size was small and therefore does not allow definitive statements about differences between germline and somatic MMR deficiency.
- The authors note that their real-world response criteria are less standardized than RECIST and may be more prone to bias or variable reliability; this is a limitation explicitly stated in the text.
- Evident from the text: this was a retrospective, single-center series with heterogeneous sarcoma subtypes and prior treatments, and the authors performed no statistical analysis of the TMB-response relationship.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
1 Valid · 0 Not valid · 20 Not checked · 22 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Additional factors beyond the high TMB and MMR status evaluated in this series likely influence the observed success of immunotherapy in sarcomas. 27 , 28”
What the sources say
- Supportedcites [27] source
The SARC028 Discussion states that 'sarcomas are highly variable in their biology and that each histologic subtype should be considered a separate therapeutic challenge that requires a distinct understanding of its immune and molecular biology', and that 'the role of PD-L1 and other potential biomarkers will be explored... to help further our understanding of the immunophenotype underlying the observed clinical differences of individual sarcoma subtypes' — i.e. factors beyond the biomarker assessed influence observed immunotherapy activity. The same Discussion backs this with concrete examples: responses in UPS and LPS 'were seen even in the absence of PD-L1 expression', PTEN loss implicated in LMS resistance, and a suppressive Treg-rich microenvironment in Ewing sarcoma. The TMB/MMR framing belongs to the citing series ('evaluated in this series'), not to this paper — SARC028 assessed PD-L1 by IHC (Methods, Immunohistochemistry and Analysis of PD-L1) and our copy contains no mention of mutational burden or mismatch repair — so the hedged general point attributed here is what the source supports. (LLM, conf=0.80)
- Not checked yetcites [28]
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The extent of response did not appear to scale with the TMB as per our observations performed without any statistical analysis”
hedgedn = 9- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In our cohort, only 1 of 6 MMR-D cases showed a response to ICI.”
plainn = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In our study, six of 16 cases with high TMB (37%) responded to ICI, which falls within the range of ICI activity observed in other tumors with high TMB (10).”
plainstates an associationn = 16- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Notably, all four cases with a UVA signature responded to ICI.”
plainstates an associationn = 4- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
8 more claims
Create a free account to see all 43 claims and to verify the 33 references still open.
- It may state two separate claims as one. 16
- Probably not a substantial claim. 18
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“the tumor agnostic criteria of high TMB (>10 mut/Mb) or MMR-D”
“a high tumor mutational burden (TMB) defined as equal to or >10 mutations per megabase (Mb)”
Citations
Cites
Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,048
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452
Garcia, E. P., Minkovsky, A., Jia, Y., Ducar, M. D., Shivdasani, P., Gong, X., Ligon, A. H., Sholl, L. M., Kuo, F. C., MacConaill, L. E., et al. (2017) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2016-0527-oa · Cited by 524
Wilky, B. A., Trucco, M. M., Subhawong, T. K., Florou, V., Park, W., Kwon, D., Wieder, E. D., Kolonias, D., Rosenberg, A. E., Kerr, D. A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30153-6 · Cited by 392
Mensenkamp, A. R., Vogelaar, I. P., van Zelst–Stams, W. A. G., Goossens, M., Ouchene, H., Hendriks–Cornelissen, S. J. B., Kwint, M. P., Hoogerbrugge, N., Nagtegaal, I. D., & Ligtenberg, M. J. L. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.002 · Cited by 328
Valero, C., Lee, M., Hoen, D., Zehir, A., Berger, M. F., Seshan, V. E., Chan, T. A., & Morris, L. G. T. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.7684 · Cited by 206
Florou, V., Rosenberg, A. E., Wieder, E., Komanduri, K. V., Kolonias, D., Uduman, M., Castle, J. C., Buell, J. S., Trent, J. C., & Wilky, B. A. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0689-7 · Cited by 185
Wagner, M. J., Othus, M., Patel, S. P., Ryan, C., Sangal, A., Powers, B., Budd, G. T., Victor, A. I., Hsueh, C.-T., Chugh, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002990 · Cited by 169
Self-citationAtezolizumab for Advanced Alveolar Soft Part Sarcoma
Chen, A. P., Sharon, E., O’Sullivan-Coyne, G., Moore, N., Foster, J. C., Hu, J. S., Van Tine, B. A., Conley, A. P., Read, W. L., Riedel, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303383 · Cited by 166
Self-citation
Research works printed but not linked: 1
- McKelvey BA, Garrett-Mayer E, Rivera DR, et al: Evaluation of real-world tumor response derived from electronic health record data sources: A feasibility analysis in patients with metastatic non-small cell lung cancer treated with chemotherapy. JCO Clin Cancer Inform 10.1200/CCI.24.00091 · doi:10.1200/cci.24.00091
Cited by
Still being checked.
Metadata
- Authors
- Alcindor, T., Papke, D. J., Venkataraman, V., Wagner, M. J., Merriam, P., Haddox, C. L., Wagner, A. J., Solimini, N. L., Jambhekar, A., & George, S.
- Affiliations
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Corresponding author
- Alcindor, Thierry
- ORCID
- Venue
- JCO Precision Oncology
- Published
- 2026-07
- Volume
- 10
- Issue
- 7
- Pages
- e2600414-e2600414
- ISSN
- 2473-4284 (ISSN-L)
- PMC
- PMC13361952
- OpenAlex
- W7167469011
- Cited by
- 0
- References
- 32
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- JCO Precision Oncology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- GlaxoSmithKline
- Eisai
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune checkpoint inhibitors, sarcoma, tumor mutational burden, mismatch repair deficiency, Lynch syndrome, radiological response, treatment response heterogeneity
- MeSH terms
- Immune Checkpoint Inhibitors, Adult, Aged, Aged, 80 and over, Brain Neoplasms, Female, Humans, Male, Middle Aged, Neoplastic Syndromes, Hereditary, Sarcoma, Colorectal Neoplasms, Tumor Burden, DNA Mismatch Repair
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency. https://app.cochat.ai/papers/10.1200/po-26-00414
- The paper
- Alcindor, T., Papke, D. J., Venkataraman, V., Wagner, M. J., Merriam, P., Haddox, C. L., Wagner, A. J., Solimini, N. L., Jambhekar, A., & George, S. (2026). Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency. JCO Precision Oncology. https://doi.org/10.1200/po-26-00414
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.